(firstQuint)DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain.

 [Double Blind Phase] The primary objective is to compare change in the Average Daily Pain Score(ADPS) from baseline to Week 14 in Asian subjects with DPNP receiving DS-5565 versus placebo.

 [Open Extension Phase] The objective is to assess the long-term safety and efficacy of DS-5565 in subjects with DPNP.

.

 DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain@highlight

Investigate the efficacy and safety of DS-5565 in subjects with Diabetic Peripheral Neuropathic Pain (DPNP) in comparison to placebo